“It is beyond the authority of the FDA for it to reach into an operating room and interfere with the reuse of a surgical patient’s own stem cells,” AAPS tells the United States Ninth Circuit Court of Appeals in an amicus brief filed on August 3, 2023. “[T]he FDA cannot properly assert for itself the power to regulate as a drug the use of a patient’s own stem cells to be reinserted back into the same patient’s own body,” concludes AAPS.
Read full brief at: https://aapsonline.org/judicial/aaps-amicus-cal-stem-cell-22-56014-08-03-2023.pdf
